Clinical trials: Sacubitril/Valsartan
Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general.
- Trial name
- NCT05168787
- Testing
- sacubitril/valsartan
- Where
- United States
- Volunteers
- 6,558 people
- Sponsor
- Methodist Health System
Chronic Heart Failure (CHF)
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState…
- Trial name
- PERSPECTIVE (NCT02884206)
- Testing
- LCZ696, Valsartan
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 592 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes…
- Trial name
- PROVIDE-HF (NCT03387163)
- Testing
- Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension, Type 2 Diabetes
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups…
- Conditions
- Essential Hypertension, Type 2 Diabetes, Nephropathy
- Trial name
- Hyper-Save (NCT06501651)
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Sichuan Academy of Medical Sciences
Hypertension
Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension
To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to…
- Trial name
- NCT04800081
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 264 people
- Sponsor
- LanZhou University
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild
[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Trial name
- NEURO-HF (NCT07856043)
- Testing
- [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Heart Failure
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2…
- Trial name
- NCT03785405
- Testing
- sacubitril/valsartan
- Where
- 79 sites in United States, Argentina and 25 more
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure, Hypertension
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
This pilot, feasibility study evaluates the efficacy of sacubitril-valsartan (Entresto) versus usual anti-hypertensive medications in patients with left ventricular assist devices (LVAD).
- Trial name
- NCT03279861
- Testing
- Entresto, Valsartan
- Sponsor
- University of Maryland, Baltimore
HIV/AIDS, Heart Failure With Preserved Ejection Fraction
The ENCHANTMENT HIV Study
Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal…
- Trial name
- NCT04153136
- Testing
- Sacubitril-Valsartan 49-51Mg Oral Tablet
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Stage D Heart Failure
Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device…
- Trial name
- SEAL-IT (NCT04191681)
- Testing
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Cleveland Clinic
PASP
Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart Failure
Evaluate effect of Sacubitril-Valsartan on estimated pulmonary artery systolic pressure in patient with reduced ejection fraction heart failure
- Trial name
- NCT07814482
- Testing
- SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Aswan University
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Heart Failure
Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
The primary objective of this prospective randomised study is to assess the safety and tolerability of sacubitril/valsartan compared with standard of care used for treating BP in patients that have been implanted with the Heart…
- Trial name
- ENVAD-HF (NCT04103554)
- Testing
- Sacubitril-Valsartan, Standard of care
- Where
- 6 sites in Croatia, Czechia and 2 more
- Volunteers
- 60 people
- Sponsor
- University of Zagreb
Heart Failure, Heart Dysfunction
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
- Trial name
- TREAT-HF (NCT05194111)
- Testing
- Sacubitril-valsartan, Valsartan, Carvedilol
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Virginia Commonwealth University
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Chagas Cardiomyopathy
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
Chagas disease is considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, having relevance in many Latin America countries.
- Trial name
- ANSWER-HF (NCT04853758)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto], Enalapril
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo General Hospital
Primary Hypertension
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate…
- Trial name
- NCT07486453
- Testing
- Sequence A T-R-T-R, Sequence B R-T-R-T
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Heart Failure
Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
The study is a cohort observational, retrospective, non-interventional study.
- Trial name
- NCT05448872
- Testing
- Sacubitril/Valsartan
- Where
- Italy
- Volunteers
- 924 people
- Sponsor
- Novartis Pharmaceuticals
Aortic Valve Insufficiency
Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
The purpose of this study is to assess the efficacy of sacubitril-valsartan compared to the combination of ARB/CCB on left ventricular remodeling in patients with chronic aortic valve regurgitation.
- Trial name
- REVERSE-AR (NCT05212597)
- Testing
- Sacubitril-valsartan, Amlodipine-losartan
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center